Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Detection of Atrial Fibrillation Using PPG From Smartphone Cameras (FLASH AF)

19 de agosto de 2026 actualizado por: Happitech BV

Detection of Atrial Fibrillation Using Photoplethysmography From Smartphone Cameras

The protocol is designed to enroll patients from at least 3 diverse clinical sites with smartphones who are being evaluated for the presence or absence of atrial fibrillation (AF) using the Heart Rhythm Software algorithm running on their smartphones. Algorithm output will be compared to a gold standard of 12-lead ECG recorded with a simultaneous PPG measurement.

Descripción general del estudio

Descripción detallada

Atrial fibrillation (AF) is the most common sustained arrhythmia worldwide, and its prevalence is increasing and is expected to continue increasing for decades,. Detection of AF episodes may be useful for the identification of undiagnosed AF and in making clinical management decisions that include oral anticoagulation, restoration and maintenance of sinus rhythm, control of ventricular rate, and risk factor modification. Treatment of AF is associated with improvements of quality of life, stroke prevention, and reduced risk of heart failure.

Traditionally, diagnosis of AF is done using an electrocardiogram, with low amplitude or absent p-waves and narrow complex "irregularly irregular" pattern intervals seen on the ECG,. After diagnosis, there are a variety of methods that can be used to manage AF. Ambulatory ECG monitoring, implantable monitoring devices, and over-the-counter wrist-worn devices have been used to manage patients with AF,,. However, these devices are inconvenient and expensive which limits their wide adoption into clinical practice. There is an unmet clinical need for an easy to use and inexpensive over-the-counter FDA-cleared products that can detect episodes of AF in real-time and notify patients to seek out further care when AF is suspected.

Recent technological advancements have allowed for the identification of AF using smartwatches, with device manufacturers gaining over-the-counter regulatory clearance for their irregular heart rate detection algorithms,. These wrist-worn devices use a light-based measurement method called photoplethysmography (PPG) to measure changes in light absorbance and reflectance to understand changes in blood flow in superficial vasculature. The waveform generated from this measurement can be used to measure parameters like pulse rate, respiratory rate, pulse rate variability and others in addition to detecting AF. The increasing ubiquity of smartphones worldwide has led to greater availability of heart rhythm diagnostics using smartphone photoplethysmography (PPG). Smartphone camera PPG technology uses the light-emitting diode in cameras to measure pulsatile changes in light intensity that are reflected from a finger and can be used to detect AF. The widespread availability of this technology has the potential to improve the accessibility and convenience of heart rhythm monitoring, particularly in remote or underserved areas. This could result in improvements in early detection and management of AF, leading to better patient outcomes. Several smartphone PPG-based algorithms have been developed that utilize smartphones' built-in cameras to detect AF. The sensitivity and specificity of these algorithms for the detection of AF range between 81%-100% and 85%-100% respectively. However, there is a lack of evidence regarding the performance of these algorithms in detecting AF in an out-of-hospital setting using a gold-standard reference.

Happitech has developed a proprietary software development kit (SDK) that can be utilized to measure patients' cardiovascular parameters and identify potential pathologies including AF. Happitech's algorithm requires users to place a digit directly against their phone camera, and the camera and underlying algorithm detect subtle differences in blood flow to calculate physiological parameters for monitoring and clinical use.

The purpose of this study is to validate the performance of Happitech's PPG-based algorithm for the detection of AF against a 12-lead ECG in a diverse population of patients including cardiology patients being evaluated as inpatients or at a cardiology clinic visit.

Tipo de estudio

De observación

Inscripción (Estimado)

554

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

  • Nombre: Yosef Safi Harb, CEO
  • Número de teléfono: +31 (0) 681885565
  • Correo electrónico: yosef@happitech.com

Copia de seguridad de contactos de estudio

  • Nombre: Amanda Marinov, Regulatory
  • Número de teléfono: +359878422979
  • Correo electrónico: a.marinov@happitech.com

Ubicaciones de estudio

    • Arkansas
      • Jonesboro, Arkansas, Estados Unidos, 72401
        • Reclutamiento
        • Nair Research, LLC dba Arrhythmia Research Group LLC
        • Contacto:
        • Investigador principal:
          • Devi Nair, Doctor
    • Colorado
      • Littleton, Colorado, Estados Unidos, 80210
        • Reclutamiento
        • South Denver Cardiology
        • Contacto:
          • Kathy Siegel, Clinical Research Director
          • Número de teléfono: 720-217-6139
          • Correo electrónico: ksiegel@southdenver.com
        • Investigador principal:
          • Srikanth Sundaram, Doctor
    • Louisiana
      • New Orleans, Louisiana, Estados Unidos, 70112
        • Aún no reclutando
        • Tulane University
        • Contacto:
          • Kunal Sameer, Associate Director of Ops
          • Número de teléfono: 203-285-5666
          • Correo electrónico: ksameer@tulane.edu
        • Investigador principal:
          • Nassair Marrouchi, Doctor
    • Oklahoma
      • Oklahoma City, Oklahoma, Estados Unidos, 73134
        • Reclutamiento
        • CardioVascular Health Clinic
        • Contacto:
        • Investigador principal:
          • Monica Lo, Doctor
    • Overijssel
      • Zwolle, Overijssel, Países Bajos, 8025 AB
        • Reclutamiento
        • Isala Zwolle
        • Contacto:
          • Fleur van Haveren, Research Cardiology
          • Número de teléfono: 088 6248377
          • Correo electrónico: f.van.haveren@isala.nl
        • Investigador principal:
          • Sebastien Krul, Doctor

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

  • Niño
  • Adulto
  • Adulto Mayor

Acepta Voluntarios Saludables

No

Método de muestreo

Muestra no probabilística

Población de estudio

Male and female patients aged 22 years or older who are cardiology patients consulting the cardiac outpatient clinic, 50% of whom have a rhythm of atrial fibrillation at the time of enrollment, and own a smartphone.

Descripción

Inclusion Criteria:

  1. Adults aged 22 years or older
  2. Owns a smartphone and knows how to operate and navigate different applications.
  3. Individuals able to read, understand, and sign the consent form.
  4. Cardiology patients consulting the cardiac outpatient clinic.
  5. History of persistent AF or other cardiac rhythm

Exclusion Criteria:

  1. Participants with cognitive impairments
  2. Individuals who cannot read, speak, and/or understand English
  3. Patients with implantable neurostimulators, cardiac implantable device in an atrial or ventricular paced rhythm documented on a 12-lead ECG during the initial study visit

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

Cohortes e Intervenciones

Grupo / Cohorte
Intervención / Tratamiento
Sinus Rhythm
Patient visiting the Cardiology Clinic in Sinus Rhythm
12 Lead ECG is compared to a smartphone based PPG
Atrial Fibrillation
Patient visiting the Cardiology Clinic in Atrial Fibrillation
12 Lead ECG is compared to a smartphone based PPG
Other
Patient visiting the Cardiology Clinic with neither Sinus Rhythm or Atrial Fibrillation
12 Lead ECG is compared to a smartphone based PPG

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
To evaluate the sensitivity and specificity of the Heart Rhythm Software
Periodo de tiempo: Through study completion, an average of 6 months

To evaluate the sensitivity and specificity of the Heart Rhythm Software algorithm running on a commercially available smartphone to detect atrial fibrillation segments using photoplethysmography (PPG) as measured through the phone's camera.

Se is defined as the percentage of patients with 90 second interval recordings scored by the Heart Rhythm Software algorithm as AF, out of all intervals determined by the Clinical Adjudication Committee (CAC) to be AF (gold standard).

Sp is defined as the percentage of patients with 90 second intervals scored by the Heart Rhythm Software algorithm as NSR out of all ECG recordings determined by the CAC to be NSR.

Through study completion, an average of 6 months

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Sensitivity & Specificity across subgroups
Periodo de tiempo: through study completion, an average of 6 months
The accuracy of the Happitech Heart Rhythm Software algorithm in detecting irregular rhythm suspected of AF and regular rhythm suspected normal sinus rhythm will be further investigated in subgroups defined by ethnicity, race, BMI, age group, smartphone type, and Fitzpatrick scale score. The sensitivity and specificity will be presented as an estimate and associated 95% CI's, as well as a Chi-square or Fisher's Exact p-value to assess if all levels of the subgroup are homogeneous.
through study completion, an average of 6 months

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

30 de junio de 2026

Finalización primaria (Estimado)

1 de noviembre de 2026

Finalización del estudio (Estimado)

1 de noviembre de 2026

Fechas de registro del estudio

Enviado por primera vez

11 de agosto de 2026

Primero enviado que cumplió con los criterios de control de calidad

19 de agosto de 2026

Publicado por primera vez (Actual)

21 de agosto de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

21 de agosto de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

19 de agosto de 2026

Última verificación

1 de agosto de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

INDECISO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

Sí

producto fabricado y exportado desde los EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir